OpenNashEarnings

IHH Healthcare (Q0F) · Health Care

IHH Healthcare Q2 2026 earnings: summary, key numbers & outlook

Results filed 27 Aug 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

IHH Healthcare's Malaysia, Türkiye & Europe and India hospitals drove Q2 growth on higher volumes and more complex cases, while Singapore recovered to 51% occupancy ahead of an expected H2 rebound.

IHH's growth came from more inpatient and daycase patients and a more complex mix of cases. Malaysia grew daycase volumes by double digits. Türkiye & Europe saw strong local and foreign demand even as beds were added at Kartal, Kent and Bayindir hospitals. India gained from the Fortis and Gleneagles integration under a maintenance services agreement. Acquisitions of Bayindir Healthcare, TMI Healthcare and Biruni Labs also added to the business.

Management is steering towards double-digit return on equity by 2028 through country-specific plans and Group-level synergies in cost, systems and operations. Priorities include selective brownfield expansion in Malaysia, faster brownfield expansion in India, and a capital-light approach in Türkiye & Europe. The main tension is Singapore, where recovery depends on lifting volumes with more price-competitive insurer packages, while costs and currency swings add pressure elsewhere.

No call transcript for this quarter, so this summary also draws on: The Star ↗, The Edge Malaysia ↗.

Key numbers

Revenue (reported) · GAAP
7.0B

up 12% year on year

PATMI (reported) · GAAP
573.0M

up 29% year on year

Core PATMI excluding exceptional items · non-GAAP
675.0M

up 30% year on year

Diluted EPS (sen) · GAAP
6.48

up 29% from a year ago

Diluted EPS excluding exceptional items (sen) · non-GAAP
6.44

up 36% from a year ago

Operating cash flow (H1 2026)
2.4B

Segment or metricValueChange
Singapore inpatient occupancy51%up from Q1 lows
Singapore margin29%
Healthcare facilities190
Net gearing0.4 times
Where each number comes from
  • Revenue (reported): “Revenue RM7.0b +12% RM6.9b +19%* EBITDA RM1.6b +19% RM1.6b +25%* PATMI (ex EI) RM569m +36% RM675m +30% PATMI RM573m +29% RM674m +28%”
  • PATMI (reported): “Revenue RM7.0b +12% RM6.9b +19%* EBITDA RM1.6b +19% RM1.6b +25%* PATMI (ex EI) RM569m +36% RM675m +30% PATMI RM573m +29% RM674m +28%”
  • Core PATMI excluding exceptional items: “Revenue RM7.0b +12% RM6.9b +19%* EBITDA RM1.6b +19% RM1.6b +25%* PATMI (ex EI) RM569m +36% RM675m +30% PATMI RM573m +29% RM674m +28%”
  • Diluted EPS (sen): “Earnings per share (sen) Basic 6.48 5.02 29% 12.46 10.85 15% Diluted 6.48 5.02 29% 12.46 10.85 15%”
  • Diluted EPS excluding exceptional items (sen): “Earnings per share, excluding EI (sen) Basic 6.44 4.75 36% 11.63 9.57 22% Diluted 6.44 4.75 36% 11.63 9.57 22%”
  • Operating cash flow (H1 2026): “Tax paid (267) (319) Net cash from operating activities 2,403 2,481 Cash flows from investing activities Interest received 153 93”
  • Singapore inpatient occupancy: “Occupancy picked up from Q1 lows to 51% in Q2 with strong margins of 29%.”
  • Singapore margin: “Occupancy picked up from Q1 lows to 51% in Q2 with strong margins of 29%.”
  • Healthcare facilities: “within and beyond our 190 healthcare facilities, including 89 hospitals.”
  • Net gearing: “Cash balance of RM1.3b as at 30 June 2026; net gearing at 0.4 times on Group-wide operational strength”

Copied from the press release ↗ and other documents in the company's results page ↗. A figure is published only if its sentence is in those documents.

Key takeaways

  1. Complex cases and higher volumes powered growth

    IHH cited more inpatient and daycase admissions and a more acute case mix across the Group. Research coverage also points to growing demand for specialised and complex care.

  2. Singapore is recovering through insurer packages

    Occupancy rose to 51% in Q2 from Q1 lows, and new packages launched with leading insurers. More price-competitive packages are expected in coming months, with recovery guided for H2 2026.

  3. India integration and brownfield expansion continue

    The Fortis and Gleneagles India maintenance services agreement is driving integration benefits alongside organic growth. IHH plans to accelerate strategic brownfield expansion to meet demand.

  4. Türkiye & Europe demand is strong and broad

    Local and foreign patient demand stayed strong even as beds were added at Kartal, Kent and Bayindir hospitals. Acibadem plans to stay capital-light while keeping market leadership.

  5. Acquisitions widen the network and diagnostics reach

    Bayindir Healthcare, TMI Healthcare and Biruni Labs were consolidated, acquired in July 2025, January 2026 and June 2026. The latest two added RM160 million of goodwill, and Biruni Labs deepens the diagnostics footprint.

Questions

What drove IHH's growth in Q2 2026?

Higher inpatient and daycase volumes and a more complex case mix, plus price adjustments and acquisitions such as Bayindir Healthcare, TMI Healthcare and Biruni Labs. Malaysia, Türkiye & Europe and India led.

How is IHH's Singapore business doing?

Occupancy recovered to 51% in Q2 from Q1 lows, and IHH launched new packages with leading insurers. More price-competitive packages are expected in coming months, with recovery guided for H2 2026.

What are IHH's strategic priorities for 2026?

In Malaysia, growing daycase and medical tourism, strengthening payor partnerships and selective brownfield expansion. In Singapore, payor partnerships and medical tourism from non-traditional markets. In India, deeper Fortis and Gleneagles integration and faster brownfield expansion; Acibadem stays capital-light.

What acquisitions did IHH consolidate recently?

Bayindir Healthcare in July 2025, TMI Healthcare in January 2026 and Biruni Labs in June 2026. TMI Healthcare and Biruni Labs together added RM160 million of goodwill.

What is IHH's long-term target?

IHH is targeting double-digit return on equity by 2028 through a multi-year transformation. It says it will use country-specific strategies and Group synergies on cost, systems and operational excellence.

Documents

Results documents

Call recording

Listen to the official replay ↗